Want to see AU:BDX full AI Analyst Report?

BCAL Diagnostics Limited (BDX) Price & Analysis

7 Followers

BDX Stock Chart & Stats

AU$0.10

>-AU$0.01(-2.06%)

At close: Jan 09 4:00 PM EST

AU$0.10

>-AU$0.01(-2.06%)

Day’s Range― - ―

52-Week RangeAU$0.05 - AU$0.16

Previous CloseN/A

Volume98.04K

Average Volume (3M)421.90K

Market Cap

AU$27.65M

Enterprise ValueAU$46.53M

Total Cash (Recent Filing)AU$3.33M

Total Debt (Recent Filing)AU$3.78M

Price to Earnings (P/E)―

Beta0.95

Next Earnings

Sep 01, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.02

Shares Outstanding368,683,300

10 Day Avg. Volume534,308

30 Day Avg. Volume421,904

Financial Highlights & Ratios

PEG Ratio0.14

Price to Book (P/B)3.64

Price to Sales (P/S)1047.06

P/FCF Ratio-3.27

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)0.01

Revenue Forecast (FY)AU$12.40M

Bulls Say, Bears Say

Bulls Say

Proprietary Diagnostic TechnologyOwning a proprietary blood-based detection technology is a durable competitive asset: it supports product differentiation, licensing or lab-service margins, and longer-term clinical adoption. If validations progress, IP and platform economics can sustain growth beyond near-term cycles.

Manageable LeverageRelatively low financial leverage reduces short-term solvency and refinancing pressure, giving management more runway to advance clinical work and commercialization. This capital structure supports flexibility to fund trials or partnerships over the next several months.

Targeted Clinical Go-to-marketA focused lab-service model for breast cancer screening creates clear clinical pathways and repeatable service revenue potential. This narrow initial market and service delivery approach aids adoption by clinicians and payers, improving chances of steady growth if clinical evidence supports efficacy.

Bears Say

Severe Revenue DeclineA near-total revenue collapse undermines operational scalability and indicates commercial traction problems or contract loss. Over several months this sharply raises the risk that R&D and validation programs cannot be sustained without new funding or strategic partnership, raising execution risk.

Negative Operating And Free Cash FlowOngoing cash burn and declining free cash flow force reliance on external financing or dilution. This constrains the company’s ability to fund clinical studies, scale lab operations, or invest in commercialization over the medium term, increasing funding and execution risk.

Deeply Negative Returns And MarginsExtremely negative margins and ROE show the company is destroying shareholder capital rather than creating value. Persisting losses impair strategic options and make attracting non-dilutive capital or commercial partnerships harder across the next several months.

BCAL Diagnostics Limited News

BCAL buys 10.2% stake in Genetic Signatures to broaden diagnostics platform

BCAL Diagnostics Limited ( ($AU:BDX) ) just unveiled an update. BCAL Diagnostics has acquired a 10.2% stake, or...

3d ago

BDX

BCAL Diagnostics secures funding to drive cancer test commercialisation through FY2027

An announcement from BCAL Diagnostics Limited ( ($AU:BDX) ) is now available. BCAL Diagnostics has strengthened its funding...

6d ago

BDX

BCAL launches blood test to monitor breast cancer recurrence

BCAL Diagnostics Limited ( ($AU:BDX) ) just unveiled an update. BCAL Diagnostics has unveiled BREASTEST Monitor, a new...

17d ago

BDX

BCAL Moves Toward U.S. Entry With Sonic Healthcare Validation Deal

BCAL Diagnostics Limited ( ($AU:BDX) ) just unveiled an update. BCAL Diagnostics has signed a validation agreement with...

1M ago

BDX

BCAL taps industry veteran Anne-Louise Arnett to spearhead cancer diagnostics rollout

The latest announcement is out from BCAL Diagnostics Limited ( ($AU:BDX) ). BCAL Diagnostics has appointed seasoned medical...

2M ago

BDX

BCAL accelerates national rollout of cancer blood tests and prepares next-gen breast screening launch

BCAL Diagnostics Limited ( ($AU:BDX) ) just unveiled an announcement. BCAL Diagnostics reported progress on the national rollout...

2M ago

BDX

BCAL seeks Medicare backing for Avantect pancreatic cancer blood test

BCAL Diagnostics Limited ( ($AU:BDX) ) just unveiled an announcement. BCAL Diagnostics has lodged an application with the...

3M ago

BDX

BCAL speeds national rollout of Avantect cancer blood tests

BCAL Diagnostics Limited ( ($AU:BDX) ) has provided an update. BCAL Diagnostics has expanded national access to its...

3M ago

BDX

BCAL Director Jayne Shaw Increases Shareholding via On‑Market Purchase

BCAL Diagnostics Limited ( ($AU:BDX) ) has issued an announcement. BCAL Diagnostics has disclosed a change in the...

4M ago

BDX

BCAL Director Jayne Shaw Increases Shareholding Via On-Market Purchase

BCAL Diagnostics Limited ( ($AU:BDX) ) has issued an update. BCAL Diagnostics has reported a change in the...

4M ago

BDX

BDX FAQ

What was BCAL Diagnostics Limited’s price range in the past 12 months?

BCAL Diagnostics Limited lowest share price was AU$0.05 and its highest was AU$0.15 in the past 12 months.

What is BCAL Diagnostics Limited’s market cap?

BCAL Diagnostics Limited’s market cap is AU$27.65M.

When is BCAL Diagnostics Limited’s upcoming earnings report date?

BCAL Diagnostics Limited’s upcoming earnings report date is Sep 01, 2026 which is in 59 days.

How were BCAL Diagnostics Limited’s earnings last quarter?

BCAL Diagnostics Limited released its earnings results on Feb 17, 2026. The company reported -AU$0.011 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.011.

Is BCAL Diagnostics Limited overvalued?

According to Wall Street analysts BCAL Diagnostics Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does BCAL Diagnostics Limited pay dividends?

BCAL Diagnostics Limited does not currently pay dividends.

What is BCAL Diagnostics Limited’s EPS estimate?

BCAL Diagnostics Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does BCAL Diagnostics Limited have?

BCAL Diagnostics Limited has 368,683,300 shares outstanding.

What happened to BCAL Diagnostics Limited’s price movement after its last earnings report?

BCAL Diagnostics Limited reported an EPS of -AU$0.011 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 4.348%.

Which hedge fund is a major shareholder of BCAL Diagnostics Limited?

Currently, no hedge funds are holding shares in AU:BDX

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

BCAL Diagnostics Limited Stock Smart Score

Neutral

Fundamentals

Return on Equity

-164.22%

Trailing 12-Months

Asset Growth

-37.01%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

BCAL Diagnostics Limited

BCAL Diagnostics Limited is a biotechnology firm focused on creating an advanced, non-surgical laboratory blood test for the identification of breast cancer. Its flagship product, the BCAL test, is a lipid biomarker-based blood assay designed for potential use in breast cancer prevention strategies, early screening, and ongoing patient monitoring. This in vitro diagnostic (IVD) technology functions by detecting a unique pattern of lipid biomarkers, which are isolated from extracellular vesicles present in a patient's plasma or blood, thereby enabling the diagnosis of breast cancer cells. Established in 2010, the company's main operations are based in Sydney, Australia.